$7.53+0.01 (+0.14%)
DarioHealth Corp.
DarioHealth Corp. in the Healthcare sector is trading at $7.53 with a market capitalization of $56M. Wall Street consensus targets $18.50 (4 analysts), implying a +145.7% move over the next 12 months. The stock is currently near its 52-week low of $5.93, remaining 28.5% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
DarioHealth Corp. operates as a digital health company in the United States and internationally. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching ...
DarioHealth Corp (DRIO) showcases revenue growth and strategic partnerships amid operational challenges and future opportunities.
DarioHealth (NASDAQ:DRIO) reported sequential revenue growth for the second straight quarter while outlining plans to expand its digital health platform further into care delivery, management said on the company’s first-quarter 2026 earnings call Wednesday. Chief Executive Officer Erez Raphael said
DarioHealth (NASDAQ:DRIO) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more. The full earnings call is available at https://viavid.webcasts.com/starthere.jsp?ei=1756269&tp_key=7306dc53e7 Summary DarioHealth reported a revenue of $5.6 million for Q1 2026, marking the second consecutive quarter of sequ
DarioHealth (DRIO) delivered earnings and revenue surprises of -14.09% and +0.25%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Si-Bone (SIBN) delivered earnings and revenue surprises of +41.18% and +2.46%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?